Baricitinib Tablets | Rheumatoid Arthritis & COVID-19 Therapy

Therapeutic Indication

Moderate to severe rheumatoid arthritis

Alopecia areata

COVID-19 (in combination with remdesivir and corticosteroids)

+91 85919 78885

Baricitinib

Tablet

Baricitinib is a Janus kinase (JAK) inhibitor that reduces inflammation by blocking intracellular signaling pathways involved in immune activation.

Speciality	Rheumatology \| Dermatology \| Infectious Diseases
Tags	Rheumatoid Arthritis \| Alopecia Areata \| COVID-19
Strength	2 mg 4 mg
Packing Size	10 Tablets

Check all Tablet Range

Click to know More

Mechanism

Baricitinib inhibits JAK1 and JAK2 enzymes, reducing cytokine signaling and immune cell activation, thereby lowering inflammation and autoimmune activity.

Pharmacokinetics

Absorption: Rapidly absorbed orally.
Metabolism: Minimal hepatic metabolism.
Excretion: Primarily via urine.
Half-life: ~12 hours.

Side Effects

Upper respiratory tract infections
Nausea
Headache
Increased cholesterol
Risk of blood clots

Contraindication

Hypersensitivity to Baricitinib
Severe renal impairment
Active infections (TB, hepatitis)

Interaction

Strong OAT3 inhibitors (probenecid)
Immunosuppressants (risk of additive effects)

Warning and Precautions

Monitor CBC, liver function, and lipid profile
Screen for TB and hepatitis before therapy
Use with caution in elderly patients

Dosage

As directed by the Physician.